Huw M. Nash - Nov 1, 2021 Form 4 Insider Report for Stoke Therapeutics, Inc. (STOK)

Role
COO & CBO
Signature
/s/ Stephen Tulipano, Attorney-in-Fact
Stock symbol
STOK
Transactions as of
Nov 1, 2021
Transactions value $
-$124,473
Form type
4
Date filed
11/3/2021, 06:05 PM
Previous filing
Oct 4, 2021
Next filing
Dec 3, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction STOK Common Stock Options Exercise $8.32K +3.8K $2.19 3.8K Nov 1, 2021 Direct
transaction STOK Common Stock Sale -$51.3K -2.19K -57.63% $23.41 1.61K Nov 1, 2021 Direct F1, F2
transaction STOK Common Stock Sale -$38.2K -1.61K -100% $23.72 0 Nov 1, 2021 Direct F1, F3
transaction STOK Common Stock Options Exercise $4.16K +1.9K $2.19 1.9K Nov 3, 2021 Direct
transaction STOK Common Stock Sale -$47.5K -1.9K -100% $25.00 0 Nov 3, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STOK Employee Stock Option (Right to Buy) Options Exercise $0 -3.8K -3.72% $0.00 98.2K Nov 1, 2021 Common Stock 3.8K $2.19 Direct F4
transaction STOK Employee Stock Option (Right to Buy) Options Exercise $0 -1.9K -1.93% $0.00 96.3K Nov 3, 2021 Common Stock 1.9K $2.19 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.67 to $23.66 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.68 to $23.76 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The option vested as to 1/48th of the total shares on November 22, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.